DE GREEF RODERICK

BLFS CEO DE GREEF RODERICK sells 100,000 shares (20.4% of holdings) across 3 trades for $2.6M at blended avg $25.80; stock -9.1% in 30 days.

DE GREEF RODERICK, President and CEO of BioLife Solutions, executed 3 separate sales totaling 100,000 shares ($2,580,421.84) over three trading days (Nov 11–13, 2025) at prices ranging from $26.15 to $25.33, reducing his holdings by 20.4% from 490,000 to 390,000 shares. The timing of this substantial liquidation is noteworthy against the company's fundamental backdrop: annual revenue declined 42.6% year-over-year, the company was unprofitable over its most recent full fiscal year, and the stock has fallen 9.1% over the past 30 days and is now 12.7% below its 52-week high. His prior sale at this ticker on 2024-10-31 showed a positive 90-day return of +20.8%, indicating that prior sale was poorly-timed relative to subsequent stock appreciation. The current significant reduction in CEO stake combined with negative revenue trends and unprofitable operations may merit close examination of operational and strategic developments.

BLFS CEO de Greef sells 37,795 shares ($1.0M) at $27.30; holds 490.0K shares post-sale as stock rallies 19.4% in 30 days.

CEO Roderick de Greef sold 37,795 shares of BIOLIFE SOLUTIONS at $27.30 on 2025-10-22, reducing his holdings to 489,998 shares, a 7.2% reduction from pre-transaction levels. The sale occurred at a significant discount to the current price of $28.79 and came amid strong recent momentum, with the stock up 19.4% over the past 30 days and 27.5% over 90 days. Notably, his prior open-market sell at BLFS on 2024-10-31 was poorly timed, with the stock rising 20.8% in the subsequent 90-day period; the same cross-ticker pattern holds across his broader trading history (avg 90d return after sells was +20.8%), suggesting his prior sales preceded rallies rather than declines. The company backdrop shows significant headwinds: annual revenue contracted 42.6%, net income was negative $15.8M on quarterly revenue of $25.4M, and the firm was unprofitable over its most recent full fiscal year. De Greef retains a substantial 490.0K share position, but the timing of this liquidation against deteriorating fundamentals and his historical pattern of selling ahead of rallies warrants attention.

CEO De Greef sold 46,896 shares of BLFS at $23.43 on 2024-10-31 (value: $1,098,773.28); stock has risen 5.4% over 30 days, now at $27.69.

De Greef sold 46,896 shares representing 10.2% of his pre-transaction holdings, executed at $23.43 when the stock was $4.26 below its current $27.69 price. The sale occurred against a backdrop of accelerating momentum—the stock is up 5.4% over 30 days and 24.7% over 90 days—and the transaction appears poorly timed in hindsight. However, the broader context reveals material headwinds: BioLife Solutions reported a most recent quarter with $30.6M in revenue but negative $1.7M net income, and the company faced an 11.4% annual revenue decline while remaining unprofitable over its latest full fiscal year. The combination of deteriorating fundamentals and a sizable reduction in the CEO's ownership stake warrants investor attention.